Department of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.
Department of Radiotherapy, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.
Head Neck. 2019 Apr;41(4):1039-1045. doi: 10.1002/hed.25523. Epub 2018 Dec 15.
We investigated the survival of patients with a p16-positive N3 oropharyngeal squamous cell carcinoma (OPSCC) and the prognostic significance of patient, tumor, and treatment characteristics.
We retrospectively reviewed the data of patients treated at our Cancer Center for a p16-positive N3 OPSCC between 2003 and 2016. End points were overall survival (OS) and progression-free survival (PFS).
A total of 29 patients were included. The 5-year OS and PFS were 67.5% and 59.1%, respectively. Smoking history above 10 pack-years and the absence of human papillomavirus DNA were associated with worse OS (P = .02 and P = .03, respectively) and PFS (P = .02 and P = .02, respectively). Induction chemotherapy or radical neck dissection were not associated with different treatment outcomes.
Patients with an N3 p16-positive oropharyngeal cancer in our series had a 5-year OS rate of 67.5%. Smoking history and viral DNA were prognostic factors associated with survival.
我们研究了 p16 阳性的 N3 口咽鳞状细胞癌（OPSCC）患者的生存情况，以及患者、肿瘤和治疗特征的预后意义。
我们回顾性分析了 2003 年至 2016 年在我们癌症中心治疗的 p16 阳性 N3 OPSCC 患者的数据。终点是总生存期（OS）和无进展生存期（PFS）。
共纳入 29 例患者。5 年 OS 和 PFS 分别为 67.5%和 59.1%。吸烟史超过 10 包年和人乳头瘤病毒 DNA 缺失与 OS（P=0.02 和 P=0.03）和 PFS（P=0.02 和 P=0.02）较差相关。诱导化疗或根治性颈清扫术与不同的治疗结果无关。
在我们的研究中，N3 p16 阳性口咽癌患者的 5 年 OS 率为 67.5%。吸烟史和病毒 DNA 是与生存相关的预后因素。
